Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer

Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer

ER+ breast cancer patients treated with endocrine therapies often acquire resistance and develop metastasis. In this study, the authors demonstrate that endocrine therapies can promote the self-renewal of CD133hi/ERlodrug resistant cells with metastatic potential driven through the IL6-Notch3 axis a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pasquale Sansone, Claudio Ceccarelli, Marjan Berishaj, Qing Chang, Vinagolu K. Rajasekhar, Fabiana Perna, Robert L. Bowman, Michele Vidone, Laura Daly, Jennifer Nnoli, Donatella Santini, Mario Taffurelli, Natalie N. C. Shih, Michael Feldman, Jun J. Mao, Christopher Colameco , Jinbo Chen, Angela DeMichele, Nicola Fabbri, John H. Healey, Monica Cricca, Giuseppe Gasparre, David Lyden, Massimiliano Bonafé, Jacqueline Bromberg
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2016
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/0f73773c836b47a9b54b97e9c2ac1634
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:ER+ breast cancer patients treated with endocrine therapies often acquire resistance and develop metastasis. In this study, the authors demonstrate that endocrine therapies can promote the self-renewal of CD133hi/ERlodrug resistant cells with metastatic potential driven through the IL6-Notch3 axis activation.

Ejemplares similares